<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354508</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230C2413</org_study_id>
    <secondary_id>2014-002630-31</secondary_id>
    <nct_id>NCT02354508</nct_id>
  </id_info>
  <brief_title>Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues</brief_title>
  <official_title>A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and
      safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly
      with maximal approved doses of first generation somatostatin analogues. The study will enroll
      inadequately controlled patients by high doses (maximal approved) of first-generation
      somatostatin analogues given for at least 3 months. Patients will receive pasireotide LAR 40
      mg or 60 mg during the 36 week core study phase. Patients who have completed all visits of
      core phase and have completed all the assessments at the core phase completion visit can move
      into the 32-week extension phase. Patients can continue with study treatment until
      pasireotide LAR is commercially available and reimbursed in their respective country or until
      the end of the extension phase whichever occurs first.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and
      safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly
      with maximal doses of first generation somatostatin analogues. The study will enroll
      inadequately controlled patients by high doses of first-generation somatostatin analogues
      given for at least 3 months.

      Patients will be categorized into two groups. Group 1 consists of patients treated with
      octreotide LAR 30 mg from countries where octreotide LAR 40mg is approved for the treatment
      of acromegaly at the time of screening. These patients will start a 3-months run-in phase to
      receive 40mg octreotide before being considered eligible to enter the core treatment phase.
      After 3 months of treatment have been completed, and prior to the fourth injection a mean GH
      and IGF-1 will be assessed. Patients who are achieving biochemical control will be considered
      a screen failure and they will not qualify for the core phase of the study. They will
      continue treatment with octreotide LAR 40 mg outside the frame of this study.

      Group 2 consists of patients treated with octreotide LAR 30 mg from countries where
      octreotide 40mg is NOT yet approved at the time of screening. This group also includes
      patients already treated with octreotide LAR 40 mg or lanreotide ATG 120 mg. Patients should
      have been treated with the first generation SSAs for at least 3 months prior to screening.
      Eligible patients can directly enter the core treatment phase of the study. A run-in phase is
      not required for this patient population.

      In the core treatment phase patients will start treatment with pasireotide LAR 40 mg every 4
      weeks. At week 12, the mean GH value and IGF-1value will be assessed. Patients who have not
      achieved biochemical control by week 12 and do not have any tolerability issues with
      pasireotide LAR 40 mg will have the dose increased to 60 mg. Patients who have achieved
      biochemical control by week 12 will maintain a dose of pasireotide LAR 40 mg. A mean GH value
      and IGF-1 value will be assessed every 12 weeks until Visit 777. At weeks 16 and 28, the
      investigator will be able to adjust the dose based on the achievement of biochemical control
      and drug tolerability. If tolerability issues occur, the dose can be decreased in 20 mg. Once
      the tolerability issue resolves, the patients should return to the dose previously received.
      Patients will be treated for a total of 36 weeks during the core phase. During this period
      any concomitant medication for the treatment of acromegaly is prohibited. Patients are
      required to complete a core phase completion visit 4 weeks after the last dose of pasireotide
      LAR is administered. Patients who discontinue from the core phase are also required to
      complete the core phase completion visit 4 weeks after receiving the last pasireotide LAR
      dose.

      Patients who have completed all visits of core phase and have completed all the assessments
      at the core phase completion visit (Visit 777) can move into the extension phase. The core
      phase completion visit performed at Visit 777, will also be the first visit (Visit 18) of the
      extension phase. At Visit 18, the patients will receive the same dose of pasireotide LAR that
      they received at week 32 (Visit 17). At week 40 (Visit 19), the investigator will decide the
      treatment regimen and the pasireotide LAR dose based on the achievement of biochemical
      control at Visit 777. Patients achieving biochemical control at the end of the core phase
      will continue pasireotide LAR monotherapy at the same dose of the core phase. Patients who
      are uncontrolled at the end of the core phase will continue pasireotide LAR 60 mg and they
      will be allowed to receive concomitant treatment with medications used to treat acromegaly
      based on the investigator's clinical judgment. GH and IGF-1 levels will be assessed every 12
      weeks until week 72. At weeks 52 and 64, the investigator will be able to adjust the dose of
      pasireotide LAR and the regimen of the concomitant medication used to acromegaly based on the
      patients achievement of biochemical control and drug tolerability. Patients will be treated
      for a total of 32 weeks in the extension phase and receive the last dose of study treatment
      at week 68 (Visit 26). Patients are required to complete an extension phase completion visit
      (Visit 778) 4 weeks after the last dose of pasireotide LAR is administered. Patients who
      prematurely discontinue from the extension phase are also required to complete the extension
      phase completion visit (Visit 778) 4 weeks after receiving the last dose of pasireotide LAR.

      After discontinuation from the study or completion of study treatment either at the core
      phase or extension phase of the study, all patients will be followed for safety for 12 weeks
      (84 days) after the last study drug administration. This visit can be performed by phone, a
      study visit for follow-up is not mandatory.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2015</start_date>
  <completion_date type="Actual">September 27, 2018</completion_date>
  <primary_completion_date type="Actual">January 8, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 by Previous Treatment and Overall</measure>
    <time_frame>Week 36</time_frame>
    <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 for Participants Up-titrated to Pasireotide LAR 60 mg</measure>
    <time_frame>Week 36</time_frame>
    <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, for participants who had been up-titrated with pasireotide LAR 60 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36</measure>
    <time_frame>Wek 36</time_frame>
    <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36</measure>
    <time_frame>Week 36</time_frame>
    <description>Percentage of patients who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, by previous treatment, type of therapy and overall.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 Overall by Baseline Diabetic Status</measure>
    <time_frame>Week 36</time_frame>
    <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, overall by baseline diabetic status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 by Previous Treatment and Overall - LOCF</measure>
    <time_frame>Week 36</time_frame>
    <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, by previous treatment and overall - last observation carried forward (LOCF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Change in Mean Growth Hormone (GH) Values From Baseline to Week 36</measure>
    <time_frame>Baseline, week 36</time_frame>
    <description>Core phase - Changes in mean GH from study baseline to week 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Change in Standardized IGF-1 Values From Baseline to Week 36</measure>
    <time_frame>Baseline, week 36</time_frame>
    <description>Core phase - Changes in standardized IGF-1 from study baseline to week 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Percentage of Participants With Mean GH &lt;1 μg/L and IGF-1 &lt;ULN</measure>
    <time_frame>Week 12, Week 24, Week 36</time_frame>
    <description>Percentage of participants achieving GH &lt;1 μg/L and IGF-1 &lt;ULN at weeks 12 and 24 overall and by GH level at screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Percentage of Participants With IGF-1 &lt;ULN Overall by GH Level at Screening</measure>
    <time_frame>Weeks 12, 24 &amp; 36</time_frame>
    <description>Percentage of participants achieving IGF-1 &lt;ULN at weeks 12, 24 &amp; 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Percentage of Participants With Mean GH &lt;1 μg/L and IGF-1 &lt;ULN Overall by Baseline Diabetic Status</measure>
    <time_frame>Weeks 12, 24 &amp; 36</time_frame>
    <description>Core phase - Percentage of patients achieving GH &lt;1μg/L at week 12, 24, 36 overall and by GH level at screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Change From Baseline in Scores as Measured by Acromegaly Quality of Life (AcroQoL)</measure>
    <time_frame>Baseline, Weeks 12, 24 &amp; 36</time_frame>
    <description>Evaluation of effect of pasireotide LAR on Health Related Quality of Life (HRQoL) was assessed using AcroQoL, an acromegaly-specific quality of life instrument. The AcroQol instrument is comprised of 22 questions divided into two scales: one evaluating physical aspects (8 items) and the other that addresses psychological aspects (14 items). The psychological scale can also be further divided into subscale that evaluates physical appearance and the other subscale focused on the impact of the disease on personal relationships of the patient (7 items each). Each of the questions has a 5-item Likert scale. For each dimension the scores range from 0-4 with 0 being the lowest impact and 4 being the most severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Percentage of Participants Reporting Levels 0 - 4 by Dimensions of Acromegaly Symptoms</measure>
    <time_frame>Weeks 12, 24 &amp; 36</time_frame>
    <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Percentage of Participants With Acromegaly Shift Symptoms From Baseline to Most Extreme Post-baseline</measure>
    <time_frame>Weeks 12, 24 &amp; 36</time_frame>
    <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Change From Baseline in EQ-5D-5L Index Scores</measure>
    <time_frame>Baseline, Weeks 12, 24 &amp; 36</time_frame>
    <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Phase: Change From Baseline in EQ-5D-5L VAS Assessment</measure>
    <time_frame>Baseline, Weeks 12, 24 &amp; 36</time_frame>
    <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Percentage of Participants With Mean GH &lt; 1 μg/L and IGF-1 &lt; ULN at Weeks 48, 60 &amp; 72 (Up-titrated to Pasireotide LAR 60 mg)</measure>
    <time_frame>Weeks 48, 60 &amp; 72</time_frame>
    <description>Percentage of patients achieving IGF-1 &lt;ULN at weeks 48, 60 &amp; 72 for participants with up-titrated to Pasireotide LAR 60 mg mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Percentage of Participants With Mean GH &lt; 1 μg/L and IGF-1 &lt; ULN at Weeks 48, 60 and 72 (Overall by Baseline Diabetic Status)</measure>
    <time_frame>Weeks 48, 60, 72</time_frame>
    <description>Percentage of participants achieving IGF-1 &lt;ULN at week 46, 60 and 72 overall by baseline diabetic status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Percentage of Participants With Mean GH &lt; 1 μg/L at Weeks 48, 60, 72 and Overall, Pasireotide Montherapy and Pasireotide With Concomittant Medication and by GH Level at Screening</measure>
    <time_frame>Weeks 48, 60, 72</time_frame>
    <description>Percentage of patients achieving GH &lt;1 μg/L and IGF-1 &lt;ULN at week 48 by treatment with pasireotide LAR alone or with concomitant medications used to treat acromegaly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Change From Baseline in Scores as Measured by Acromegaly Quality of Life (AcroQoL)</measure>
    <time_frame>Baseline, Weeks 48, 60 &amp; 72</time_frame>
    <description>Evaluation of effect of pasireotide LAR on Health Related Quality of Life (HRQoL) was assessed using AcroQoL, an acromegaly-specific quality of life instrument. The AcroQol instrument is comprised of 22 questions divided into two scales: one evaluating physical aspects (8 items) and the other that addresses psychological aspects (14 items). The psychological scale can also be further divided into subscale that evaluates physical appearance and the other subscale focused on the impact of the disease on personal relationships of the patient (7 items each). Each of the questions has a 5-item Likert scale. For each dimension the scores range from 0-4 with 0 being the lowest impact and 4 being the most severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Percentage of Participants Reporting Levels 1 - 5 by Dimensions of Acromegaly Symptoms</measure>
    <time_frame>Weeks 48, 60 &amp; 72</time_frame>
    <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension (Ext.) Phase: Percentage of Participants With Acromegaly Shift Symptoms From Extension Baseline to Most Extreme Post-extension Baseline</measure>
    <time_frame>Weeks 48, 60 &amp; 72</time_frame>
    <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Change From Baseline in EQ-5D-5L Index Scores</measure>
    <time_frame>Baseline, Weeks 48, 60 &amp; 72</time_frame>
    <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Change From Baseline in EQ-5D-5L VAS Assessment</measure>
    <time_frame>Baseline, Weeks 48, 60 &amp; 72</time_frame>
    <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Pasireotide LAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who qualify for the core phase of the study will be treated with pasireotide LAR 40 mg initially. Patients not achieving biochemical control can be up-titrated to pasireotide LAR 60 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide LAR</intervention_name>
    <description>Pasireotide 40 mg and 60 mg. Pasireotide 20 mg which was allowed for dose decrease in case of adverse event.</description>
    <arm_group_label>Pasireotide LAR</arm_group_label>
    <other_name>SOM230</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Male and female patients ≥18 years

          -  Patients with confirmed diagnosis of inadequately controlled acromegaly (mean GH
             concentration ≥1 μg/L and sex- and age-adjusted IGF-1 &gt;1.3 x ULN)

          -  Patients treated with octreotide LAR (30 mg or 40 mg) or lanreotide ATG (120 mg)
             monotherapy for at least 3 months prior to screening

        Exclusion Criteria:

          -  Concomitant treatment with other medications reducing GH and or IGF-1, unless
             discontinued 3 months prior to screening

          -  Patients with compression of the optic chiasm requiring surgical intervention

          -  Diabetic patients with HbA1c &gt;8% at screening

          -  Patients who are hypothyroid and not on adequate replacement therapy

          -  Patients with symptomatic cholelithiasis and acute or chronic pancreatitis

          -  Patients with clinically significant valvular disease

          -  Patients with risk factors for torsade de pointes (TdP)

          -  Hypokalaemia, hypomagnesaemia, uncontrolled hypothyroidism, family history of long QT
             syndrome or concomitant medications with known risk of TdP

          -  Patients with congestive heart failure (NYHA Class III or IV), unstable angina,
             sustained ventricular tachycardia, clinically significant bradycardia, advanced heart
             block, history of acute MI less than one year prior to study entry or clinically
             significant impairment in cardiovascular function.

          -  Concomitant disease(s) that could prolong the QT interval such as autonomic neuropathy
             (caused by diabetes or Parkinson's disease), HIV, cirrhosis, uncontrolled
             hypothyroidism or cardiac failure

          -  Patients with liver disease or ALT/AST &gt; 2.0 X ULN, serum bilirubin &gt;2.0 X ULN -
             Presence of Hepatitis B surface antigen or Hepatitis C antibody test

          -  Patients with serum creatinine &gt;2.0 X ULN

          -  Patients with WBC &lt;3 X 109/L; Hb 90% &lt; LLN; PLT &lt;100 X 109/L

          -  Patients with active or suspected acute or chronic uncontrolled infection

          -  Patients who have undergone major surgery/surgical therapy within 4 weeks prior to
             screening

          -  Patients with active malignant disease within the last five years (with the exception
             of basal cell carcinoma or carcinoma in situ of the cervix)

          -  Patients with abnormal coagulation (PT and/or APTT elevated by 30% above normal
             limits) or patients receiving anticoagulants that affect PT (prothrombin time) or APTT
             (activated partial thromboplastin time)

          -  History of syncope or family history of idiopathic sudden death

          -  History of immunocompromise, including a positive HIV test result (ELISA and Western
             blot)

          -  Known hypersensitivity to somatostatin analogues or any other component of pasireotide
             LAR

          -  Patients who have a history of alcohol or drug abuse in the 6 month period prior to
             receiving pasireotide

          -  Patients who have given a blood donation (of 400 ml or more) within 2 months before
             receiving pasireotide

          -  Patients who have participated in any clinical investigation with an investigational
             drug within 1 month prior to dosing

          -  Patients with any current or prior medical condition interfering with the conduct of
             the study or the evaluation of the study results

          -  Patients with a history of non-compliance to medical regimens or who are considered
             potentially unreliable or will be unable to complete the entire study.

          -  Sexually active males unless they use a condom during intercourse while taking drug
             and for 3 months following last dose of pasireotide

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             during dosing and 3 months following the last dose of pasireotide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7602CBM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-590</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Floridablanca</city>
        <state>Santander</state>
        <zip>57-7</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angers cedex 09</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Besancon cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nimes Cedex</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <state>HUN</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilayah Persekutuan</city>
        <zip>62502</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>02990</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durango</city>
        <zip>34270</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1349 019</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>011863</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iasi</city>
        <zip>700127</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <state>TUR</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06560</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pendik / Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <results_first_submitted>September 26, 2019</results_first_submitted>
  <results_first_submitted_qc>November 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2019</results_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acromegaly</keyword>
  <keyword>GH</keyword>
  <keyword>IGF-1</keyword>
  <keyword>pasireotide LAR</keyword>
  <keyword>SOM230</keyword>
  <keyword>first generation</keyword>
  <keyword>somatostatin analogues</keyword>
  <keyword>growth disorder</keyword>
  <keyword>gigantism</keyword>
  <keyword>Pituitary adenoma</keyword>
  <keyword>pituitary gigantism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 5, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02354508/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02354508/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Planned 112 participants and analyzed 123 participants. For Participant Flow/Baseline Characteristics Tables, Total = Participants in the Pasireotide LAR arm.</recruitment_details>
      <pre_assignment_details>Participants were allocated to Group 1 or Group 2 based on previously received first generation Somatostatin analog (SSA).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lanreotide 120 mg</title>
          <description>Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).</description>
        </group>
        <group group_id="P2">
          <title>Octreotide 30 mg</title>
          <description>Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .</description>
        </group>
        <group group_id="P3">
          <title>Octreotide 40 mg</title>
          <description>Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Core Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">not all patients who completed the Core phase went into the Extension phase</participants>
                <participants group_id="P2" count="23">not all patients who completed the Core phase went into the Extension phase</participants>
                <participants group_id="P3" count="39">not all patients who completed the Core phase went into the Extension phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3: Post-treatment Follow up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Post-treatment f/up Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="4">Entered post-treatment follow-up, discontinued</participants>
                <participants group_id="P2" count="3">Entered post-treatment follow-up, discontinued</participants>
                <participants group_id="P3" count="3">Entered post-treatment follow-up, discontinued</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22">Entered post-treatment follow-up, completed</participants>
                <participants group_id="P2" count="20">Entered post-treatment follow-up, completed</participants>
                <participants group_id="P3" count="36">Entered post-treatment follow-up, completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Lanreotide 120 mg</title>
          <description>Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).</description>
        </group>
        <group group_id="B2">
          <title>Octreotide 30 mg</title>
          <description>Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .</description>
        </group>
        <group group_id="B3">
          <title>Octreotide 40 mg</title>
          <description>Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="53"/>
            <count group_id="B4" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="10.02"/>
                    <measurement group_id="B2" value="41.6" spread="12.89"/>
                    <measurement group_id="B3" value="46.6" spread="11.63"/>
                    <measurement group_id="B4" value="43.8" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 by Previous Treatment and Overall</title>
        <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36.</description>
        <time_frame>Week 36</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide 120 mg</title>
            <description>Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O2">
            <title>Octreotide 30 mg</title>
            <description>Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .</description>
          </group>
          <group group_id="O3">
            <title>Octreotide 40 mg</title>
            <description>Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 by Previous Treatment and Overall</title>
          <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36.</description>
          <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="5.57" upper_limit="29.17"/>
                    <measurement group_id="O2" value="13.8" lower_limit="3.89" upper_limit="31.66"/>
                    <measurement group_id="O3" value="15.1" lower_limit="6.75" upper_limit="27.59"/>
                    <measurement group_id="O4" value="14.6" lower_limit="8.91" upper_limit="22.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 for Participants Up-titrated to Pasireotide LAR 60 mg</title>
        <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, for participants who had been up-titrated with pasireotide LAR 60 mg.</description>
        <time_frame>Week 36</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study. For these patients the Pasireotide LAR dose was uptitrated to 60 mg before Week 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Up-titrated to Pasireotide LAR 60 mg</title>
            <description>This is the subset of participants in the FAS who started treatment with 40 mg pasireotide LAR in the core phase and were up-titrated to pasireotide LAR 60 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 for Participants Up-titrated to Pasireotide LAR 60 mg</title>
          <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, for participants who had been up-titrated with pasireotide LAR 60 mg.</description>
          <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study. For these patients the Pasireotide LAR dose was uptitrated to 60 mg before Week 36.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="2.49" upper_limit="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36</title>
        <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36.</description>
        <time_frame>Wek 36</time_frame>
        <population>Per-Protocol Set (PPS): consisted of a subset of the patients in the FAS who were compliant with requirements of the clinical study protocol. The protocol deviations criteria were defined prior to database lock. Per-protocol analysis was performed during the core phase, but not during the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36</title>
          <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36.</description>
          <population>Per-Protocol Set (PPS): consisted of a subset of the patients in the FAS who were compliant with requirements of the clinical study protocol. The protocol deviations criteria were defined prior to database lock. Per-protocol analysis was performed during the core phase, but not during the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="9.24" upper_limit="24.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36</title>
        <description>Percentage of patients who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, by previous treatment, type of therapy and overall.</description>
        <time_frame>Week 36</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide 120 mg</title>
            <description>Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O2">
            <title>Octreotide 30 mg</title>
            <description>Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .</description>
          </group>
          <group group_id="O3">
            <title>Octreotide 40 mg</title>
            <description>Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Monotherapy</title>
            <description>Participants received pasireotide LAR only</description>
          </group>
          <group group_id="O5">
            <title>Pasireotide With Concomitant Medication</title>
            <description>Participants received pasireotide along with other concomitant medications.or octreotide 40 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36</title>
          <description>Percentage of patients who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, by previous treatment, type of therapy and overall.</description>
          <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="0.95" upper_limit="25.13"/>
                    <measurement group_id="O2" value="13.0" lower_limit="2.78" upper_limit="33.59"/>
                    <measurement group_id="O3" value="20.5" lower_limit="9.30" upper_limit="36.46"/>
                    <measurement group_id="O4" value="17.1" lower_limit="9.43" upper_limit="27.47"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                    <measurement group_id="O6" value="14.8" lower_limit="8.11" upper_limit="23.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 for Participants Up-titrated to Pasireotide LAR 60 mg</title>
        <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, for participants who had been up-titrated with pasireotide LAR 60 mg.</description>
        <time_frame>Week 36</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study. For these patients the Pasireotide LAR dose was uptitrated to 60 mg any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Up-titrated to Pasireotide LAR 60 mg</title>
            <description>This is the subset of participants in the Extension FAS who started treatment with 40 mg pasireotide LAR in the extension phase and were up-titrated to pasireotide LAR 60 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 for Participants Up-titrated to Pasireotide LAR 60 mg</title>
          <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, for participants who had been up-titrated with pasireotide LAR 60 mg.</description>
          <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study. For these patients the Pasireotide LAR dose was uptitrated to 60 mg any time during the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="1.63" upper_limit="14.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 Overall by Baseline Diabetic Status</title>
        <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, overall by baseline diabetic status.</description>
        <time_frame>Week 36</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 Overall by Baseline Diabetic Status</title>
          <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, overall by baseline diabetic status.</description>
          <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="5.30" upper_limit="27.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="8.19" upper_limit="36.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="33.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 by Previous Treatment and Overall - LOCF</title>
        <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, by previous treatment and overall - last observation carried forward (LOCF)</description>
        <time_frame>Week 36</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide 120 mg</title>
            <description>Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O2">
            <title>Octreotide 30 mg</title>
            <description>Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .</description>
          </group>
          <group group_id="O3">
            <title>Octreotide 40 mg</title>
            <description>Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Mean GH &lt; 1 g/L and IGF-1 &lt; ULN at Week 36 by Previous Treatment and Overall - LOCF</title>
          <description>Percentage of participants who achieved biochemical control defined as GH &lt;1μg/L and IGF-1 &lt;ULN at week 36, by previous treatment and overall - last observation carried forward (LOCF)</description>
          <population>Full Analysis Set (FAS) comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="5.57" upper_limit="29.17"/>
                    <measurement group_id="O2" value="13.8" lower_limit="3.89" upper_limit="31.66"/>
                    <measurement group_id="O3" value="17.0" lower_limit="8.07" upper_limit="29.80"/>
                    <measurement group_id="O4" value="15.4" lower_limit="9.56" upper_limit="23.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Change in Mean Growth Hormone (GH) Values From Baseline to Week 36</title>
        <description>Core phase - Changes in mean GH from study baseline to week 36.</description>
        <time_frame>Baseline, week 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide 120 mg</title>
            <description>Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O2">
            <title>Octreotide 30 mg</title>
            <description>Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .</description>
          </group>
          <group group_id="O3">
            <title>Octreotide 40 mg</title>
            <description>Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Change in Mean Growth Hormone (GH) Values From Baseline to Week 36</title>
          <description>Core phase - Changes in mean GH from study baseline to week 36.</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="19.51"/>
                    <measurement group_id="O2" value="-8.5" spread="24.41"/>
                    <measurement group_id="O3" value="-2.9" spread="4.21"/>
                    <measurement group_id="O4" value="-6.0" spread="17.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Change in Standardized IGF-1 Values From Baseline to Week 36</title>
        <description>Core phase - Changes in standardized IGF-1 from study baseline to week 36.</description>
        <time_frame>Baseline, week 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide 120 mg</title>
            <description>Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O2">
            <title>Octreotide 30 mg</title>
            <description>Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .</description>
          </group>
          <group group_id="O3">
            <title>Octreotide 40 mg</title>
            <description>Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Change in Standardized IGF-1 Values From Baseline to Week 36</title>
          <description>Core phase - Changes in standardized IGF-1 from study baseline to week 36.</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.18"/>
                    <measurement group_id="O2" value="-0.8" spread="0.78"/>
                    <measurement group_id="O3" value="-1.1" spread="1.39"/>
                    <measurement group_id="O4" value="-1.0" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Percentage of Participants With Mean GH &lt;1 μg/L and IGF-1 &lt;ULN</title>
        <description>Percentage of participants achieving GH &lt;1 μg/L and IGF-1 &lt;ULN at weeks 12 and 24 overall and by GH level at screening.</description>
        <time_frame>Week 12, Week 24, Week 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR (run-in Phase)</title>
            <description>Participants who were part of the run-in phase, i.e. group 1)</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Mean GH &lt;1 μg/L and IGF-1 &lt;ULN</title>
          <description>Percentage of participants achieving GH &lt;1 μg/L and IGF-1 &lt;ULN at weeks 12 and 24 overall and by GH level at screening.</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12: GH: ≥ 1 - ≤ 2.5 μg/L @ screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0.63" upper_limit="80.59"/>
                    <measurement group_id="O2" value="28.6" lower_limit="13.22" upper_limit="48.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: GH: ≥ 1 - ≤ 2.5 μg/L @ screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0.63" upper_limit="80.59"/>
                    <measurement group_id="O2" value="39.3" lower_limit="21.50" upper_limit="59.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: GH: ≥ 1 - ≤ 2.5 μg/L @ screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0.63" upper_limit="80.59"/>
                    <measurement group_id="O2" value="42.9" lower_limit="24.46" upper_limit="62.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: GH: &gt; 2.5 μg/L @ screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="0.19" upper_limit="36.03"/>
                    <measurement group_id="O2" value="5.3" lower_limit="1.75" upper_limit="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: GH: &gt; 2.5 μg/L @ screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="0.19" upper_limit="36.03"/>
                    <measurement group_id="O2" value="5.3" lower_limit="1.75" upper_limit="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: GH: &gt; 2.5 μg/L @ screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="0.19" upper_limit="36.03"/>
                    <measurement group_id="O2" value="6.4" lower_limit="2.38" upper_limit="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: GH: Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="97.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: GH: Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="97.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: GH: Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="97.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Percentage of Participants With IGF-1 &lt;ULN Overall by GH Level at Screening</title>
        <description>Percentage of participants achieving IGF-1 &lt;ULN at weeks 12, 24 &amp; 36.</description>
        <time_frame>Weeks 12, 24 &amp; 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
        <group_list>
          <group group_id="O1">
            <title>GH: ≥1 - ≤ 2.5 μg/L</title>
            <description>These Participants had this GH level at screening</description>
          </group>
          <group group_id="O2">
            <title>GH: &gt; 2.5 μg/L</title>
            <description>These Participants had this GH level at screening</description>
          </group>
          <group group_id="O3">
            <title>GH: Missing</title>
            <description>These Participants were missing GH levels at screening</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall</title>
            <description>This is the total sum of participants with at screening with various or missing GH levels</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With IGF-1 &lt;ULN Overall by GH Level at Screening</title>
          <description>Percentage of participants achieving IGF-1 &lt;ULN at weeks 12, 24 &amp; 36.</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="18.64" upper_limit="55.93"/>
                    <measurement group_id="O2" value="16.0" lower_limit="9.22" upper_limit="24.95"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="97.50"/>
                    <measurement group_id="O4" value="20.3" lower_limit="13.61" upper_limit="28.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="24.46" upper_limit="62.82"/>
                    <measurement group_id="O2" value="23.4" lower_limit="15.29" upper_limit="33.26"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="97.50"/>
                    <measurement group_id="O4" value="27.6" lower_limit="19.96" upper_limit="36.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="30.65" upper_limit="69.35"/>
                    <measurement group_id="O2" value="25.5" lower_limit="17.09" upper_limit="35.57"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="97.50"/>
                    <measurement group_id="O4" value="30.9" lower_limit="22.88" upper_limit="39.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Percentage of Participants With Mean GH &lt;1 μg/L and IGF-1 &lt;ULN Overall by Baseline Diabetic Status</title>
        <description>Core phase - Percentage of patients achieving GH &lt;1μg/L at week 12, 24, 36 overall and by GH level at screening.</description>
        <time_frame>Weeks 12, 24 &amp; 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetic</title>
            <description>Participants who were diabetic in the Pasireotide LAR overall group</description>
          </group>
          <group group_id="O2">
            <title>Pre-diabetic</title>
            <description>Participants who were pre-diabetic in the Pasireotide LAR overall group</description>
          </group>
          <group group_id="O3">
            <title>Non-diabetic</title>
            <description>Participants who were non-diabetic in the Pasireotide LAR overall group</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Mean GH &lt;1 μg/L and IGF-1 &lt;ULN Overall by Baseline Diabetic Status</title>
          <description>Core phase - Percentage of patients achieving GH &lt;1μg/L at week 12, 24, 36 overall and by GH level at screening.</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="5.59" upper_limit="25.79"/>
                    <measurement group_id="O2" value="10.0" lower_limit="3.76" upper_limit="20.51"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="28.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="5.59" upper_limit="25.79"/>
                    <measurement group_id="O2" value="13.3" lower_limit="5.94" upper_limit="24.59"/>
                    <measurement group_id="O3" value="9.1" lower_limit="0.23" upper_limit="41.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="6.88" upper_limit="28.08"/>
                    <measurement group_id="O2" value="16.7" lower_limit="8.29" upper_limit="28.52"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="28.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Change From Baseline in Scores as Measured by Acromegaly Quality of Life (AcroQoL)</title>
        <description>Evaluation of effect of pasireotide LAR on Health Related Quality of Life (HRQoL) was assessed using AcroQoL, an acromegaly-specific quality of life instrument. The AcroQol instrument is comprised of 22 questions divided into two scales: one evaluating physical aspects (8 items) and the other that addresses psychological aspects (14 items). The psychological scale can also be further divided into subscale that evaluates physical appearance and the other subscale focused on the impact of the disease on personal relationships of the patient (7 items each). Each of the questions has a 5-item Likert scale. For each dimension the scores range from 0-4 with 0 being the lowest impact and 4 being the most severe.</description>
        <time_frame>Baseline, Weeks 12, 24 &amp; 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall - AcroQOL Total Scores</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide LAR Overall - AcroQOL Physical Sub-scores</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg</description>
          </group>
          <group group_id="O3">
            <title>Pasireotide LAR Overall - AcroQOL Psychological Sub-scores</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall - AcroQOL Psycho/Appearance Sub-scores</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg</description>
          </group>
          <group group_id="O5">
            <title>Pasireotide LAR Overall-AcroQOL Psycho/Pers Relatns Sub-scores</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Change From Baseline in Scores as Measured by Acromegaly Quality of Life (AcroQoL)</title>
          <description>Evaluation of effect of pasireotide LAR on Health Related Quality of Life (HRQoL) was assessed using AcroQoL, an acromegaly-specific quality of life instrument. The AcroQol instrument is comprised of 22 questions divided into two scales: one evaluating physical aspects (8 items) and the other that addresses psychological aspects (14 items). The psychological scale can also be further divided into subscale that evaluates physical appearance and the other subscale focused on the impact of the disease on personal relationships of the patient (7 items each). Each of the questions has a 5-item Likert scale. For each dimension the scores range from 0-4 with 0 being the lowest impact and 4 being the most severe.</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="120"/>
                    <count group_id="O4" value="120"/>
                    <count group_id="O5" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="9.52"/>
                    <measurement group_id="O2" value="5.3" spread="12.93"/>
                    <measurement group_id="O3" value="4.1" spread="10.05"/>
                    <measurement group_id="O4" value="6.5" spread="12.43"/>
                    <measurement group_id="O5" value="1.9" spread="12.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="118"/>
                    <count group_id="O5" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="9.88"/>
                    <measurement group_id="O2" value="5.8" spread="12.26"/>
                    <measurement group_id="O3" value="4.0" spread="10.72"/>
                    <measurement group_id="O4" value="7.2" spread="14.44"/>
                    <measurement group_id="O5" value="0.9" spread="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="110"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="110"/>
                    <count group_id="O5" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="10.14"/>
                    <measurement group_id="O2" value="5.4" spread="13.00"/>
                    <measurement group_id="O3" value="4.3" spread="11.02"/>
                    <measurement group_id="O4" value="7.0" spread="15.33"/>
                    <measurement group_id="O5" value="1.8" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Percentage of Participants Reporting Levels 0 - 4 by Dimensions of Acromegaly Symptoms</title>
        <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
        <time_frame>Weeks 12, 24 &amp; 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Headache</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Fatigue</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg</description>
          </group>
          <group group_id="O3">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Perspiration</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Osteoarthralgia</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg</description>
          </group>
          <group group_id="O5">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Paresthesiae</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants Reporting Levels 0 - 4 by Dimensions of Acromegaly Symptoms</title>
          <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12: Non/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9"/>
                    <measurement group_id="O2" value="37.4"/>
                    <measurement group_id="O3" value="56.9"/>
                    <measurement group_id="O4" value="43.1"/>
                    <measurement group_id="O5" value="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="26.8"/>
                    <measurement group_id="O4" value="27.6"/>
                    <measurement group_id="O5" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="18.7"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="14.6"/>
                    <measurement group_id="O5" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="8.9"/>
                    <measurement group_id="O5" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="2.4"/>
                    <measurement group_id="O5" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Non/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3"/>
                    <measurement group_id="O2" value="46.3"/>
                    <measurement group_id="O3" value="64.2"/>
                    <measurement group_id="O4" value="47.2"/>
                    <measurement group_id="O5" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="20.3"/>
                    <measurement group_id="O3" value="21.1"/>
                    <measurement group_id="O4" value="26.8"/>
                    <measurement group_id="O5" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="8.9"/>
                    <measurement group_id="O4" value="14.6"/>
                    <measurement group_id="O5" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="3.3"/>
                    <measurement group_id="O5" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="0.8"/>
                    <measurement group_id="O4" value="4.9"/>
                    <measurement group_id="O5" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="119"/>
                    <count group_id="O5" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Non/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="113"/>
                    <count group_id="O4" value="113"/>
                    <count group_id="O5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="61.8"/>
                    <measurement group_id="O4" value="47.2"/>
                    <measurement group_id="O5" value="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="113"/>
                    <count group_id="O4" value="113"/>
                    <count group_id="O5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1"/>
                    <measurement group_id="O2" value="23.6"/>
                    <measurement group_id="O3" value="18.7"/>
                    <measurement group_id="O4" value="26.8"/>
                    <measurement group_id="O5" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="113"/>
                    <count group_id="O4" value="113"/>
                    <count group_id="O5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="12.2"/>
                    <measurement group_id="O5" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="113"/>
                    <count group_id="O4" value="113"/>
                    <count group_id="O5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="4.1"/>
                    <measurement group_id="O4" value="3.3"/>
                    <measurement group_id="O5" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="113"/>
                    <count group_id="O4" value="113"/>
                    <count group_id="O5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.4"/>
                    <measurement group_id="O5" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36: Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="113"/>
                    <count group_id="O4" value="113"/>
                    <count group_id="O5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Percentage of Participants With Acromegaly Shift Symptoms From Baseline to Most Extreme Post-baseline</title>
        <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
        <time_frame>Weeks 12, 24 &amp; 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Headache</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Fatigue</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg</description>
          </group>
          <group group_id="O3">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Perspiration</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Osteoarthralgia</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg</description>
          </group>
          <group group_id="O5">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Paresthsiae</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Percentage of Participants With Acromegaly Shift Symptoms From Baseline to Most Extreme Post-baseline</title>
          <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL): Non/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5"/>
                    <measurement group_id="O2" value="36.6"/>
                    <measurement group_id="O3" value="43.1"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="17.8"/>
                    <measurement group_id="O3" value="25.2"/>
                    <measurement group_id="O4" value="21.1"/>
                    <measurement group_id="O5" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7"/>
                    <measurement group_id="O2" value="26.0"/>
                    <measurement group_id="O3" value="18.7"/>
                    <measurement group_id="O4" value="26.0"/>
                    <measurement group_id="O5" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="8.9"/>
                    <measurement group_id="O4" value="16.3"/>
                    <measurement group_id="O5" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="4.1"/>
                    <measurement group_id="O4" value="3.3"/>
                    <measurement group_id="O5" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL: Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>BL: Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="123"/>
                    <count group_id="O4" value="123"/>
                    <count group_id="O5" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr post-BL:tot Non/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="26.0"/>
                    <measurement group_id="O3" value="37.4"/>
                    <measurement group_id="O4" value="26.8"/>
                    <measurement group_id="O5" value="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL: total Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9"/>
                    <measurement group_id="O2" value="22.8"/>
                    <measurement group_id="O3" value="29.3"/>
                    <measurement group_id="O4" value="26.0"/>
                    <measurement group_id="O5" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL: total Mod.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="22.8"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="24.4"/>
                    <measurement group_id="O5" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL: total Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="15.4"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="14.6"/>
                    <measurement group_id="O5" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr post-BL:tot. Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="5.7"/>
                    <measurement group_id="O4" value="8.1"/>
                    <measurement group_id="O5" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL: total Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Change From Baseline in EQ-5D-5L Index Scores</title>
        <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
        <time_frame>Baseline, Weeks 12, 24 &amp; 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Change From Baseline in EQ-5D-5L Index Scores</title>
          <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Core Phase: Change From Baseline in EQ-5D-5L VAS Assessment</title>
        <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
        <time_frame>Baseline, Weeks 12, 24 &amp; 36</time_frame>
        <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Core Phase: Change From Baseline in EQ-5D-5L VAS Assessment</title>
          <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
          <population>FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="15.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Percentage of Participants With Mean GH &lt; 1 μg/L and IGF-1 &lt; ULN at Weeks 48, 60 &amp; 72 (Up-titrated to Pasireotide LAR 60 mg)</title>
        <description>Percentage of patients achieving IGF-1 &lt;ULN at weeks 48, 60 &amp; 72 for participants with up-titrated to Pasireotide LAR 60 mg mg</description>
        <time_frame>Weeks 48, 60 &amp; 72</time_frame>
        <population>Extension Full Analysis Set (Extension FAS) included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Up-titrated to Pasireotide LAR 60 mg</title>
            <description>This is the subset of participants in the FAS who started treatment with 40 mg pasireotide LAR in the core phase and were up-titrated to pasireotide LAR 60 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Percentage of Participants With Mean GH &lt; 1 μg/L and IGF-1 &lt; ULN at Weeks 48, 60 &amp; 72 (Up-titrated to Pasireotide LAR 60 mg)</title>
          <description>Percentage of patients achieving IGF-1 &lt;ULN at weeks 48, 60 &amp; 72 for participants with up-titrated to Pasireotide LAR 60 mg mg</description>
          <population>Extension Full Analysis Set (Extension FAS) included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="1.60" upper_limit="14.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="2.36" upper_limit="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="1.58" upper_limit="13.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Percentage of Participants With Mean GH &lt; 1 μg/L and IGF-1 &lt; ULN at Weeks 48, 60 and 72 (Overall by Baseline Diabetic Status)</title>
        <description>Percentage of participants achieving IGF-1 &lt;ULN at week 46, 60 and 72 overall by baseline diabetic status</description>
        <time_frame>Weeks 48, 60, 72</time_frame>
        <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall</title>
            <description>These are the participants in the extension phase who received Pasireotide LAR</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Percentage of Participants With Mean GH &lt; 1 μg/L and IGF-1 &lt; ULN at Weeks 48, 60 and 72 (Overall by Baseline Diabetic Status)</title>
          <description>Percentage of participants achieving IGF-1 &lt;ULN at week 46, 60 and 72 overall by baseline diabetic status</description>
          <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48: Diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="3.89" upper_limit="25.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="3.89" upper_limit="25.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="3.89" upper_limit="25.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Pre-diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="3.11" upper_limit="26.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Pre-diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="6.37" upper_limit="32.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Pre-diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="1.75" upper_limit="22.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Non-diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="2.81" upper_limit="60.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Non-diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="2.81" upper_limit="60.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Non-diabetic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="2.81" upper_limit="60.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Percentage of Participants With Mean GH &lt; 1 μg/L at Weeks 48, 60, 72 and Overall, Pasireotide Montherapy and Pasireotide With Concomittant Medication and by GH Level at Screening</title>
        <description>Percentage of patients achieving GH &lt;1 μg/L and IGF-1 &lt;ULN at week 48 by treatment with pasireotide LAR alone or with concomitant medications used to treat acromegaly</description>
        <time_frame>Weeks 48, 60, 72</time_frame>
        <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Monotherapy</title>
            <description>These Participants were treated with pasireotide LAR only in the extension phase</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide With Concomitant Mediaction</title>
            <description>These Participants were treated with pasireotide LAR as well as other concomitant medications in the extension phase</description>
          </group>
          <group group_id="O3">
            <title>Pasireotide LAR Overall</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Percentage of Participants With Mean GH &lt; 1 μg/L at Weeks 48, 60, 72 and Overall, Pasireotide Montherapy and Pasireotide With Concomittant Medication and by GH Level at Screening</title>
          <description>Percentage of patients achieving GH &lt;1 μg/L and IGF-1 &lt;ULN at week 48 by treatment with pasireotide LAR alone or with concomitant medications used to treat acromegaly</description>
          <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk48:GH: &gt;= 1 - &lt;= 2.5 μg/L at screen.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="50.10" upper_limit="93.19"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="70.76"/>
                    <measurement group_id="O3" value="65.0" lower_limit="40.78" upper_limit="84.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk60:GH: &gt;= 1 - &lt;= 2.5 μg/L at screen.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" lower_limit="44.04" upper_limit="89.69"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="70.76"/>
                    <measurement group_id="O3" value="60.0" lower_limit="36.05" upper_limit="80.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk72:GH: &gt;= 1 - &lt;= 2.5 μg/L at screen.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" lower_limit="38.33" upper_limit="85.79"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="70.76"/>
                    <measurement group_id="O3" value="55.0" lower_limit="31.53" upper_limit="76.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk48: GH: &gt; 2.5 μg/L at screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="4.91" upper_limit="22.93"/>
                    <measurement group_id="O2" value="11.1" lower_limit="0.28" upper_limit="48.25"/>
                    <measurement group_id="O3" value="11.8" lower_limit="5.22" upper_limit="21.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk60: GH: &gt; 2.5 μg/L at screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="4.91" upper_limit="22.93"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="33.63"/>
                    <measurement group_id="O3" value="10.3" lower_limit="4.24" upper_limit="20.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk72: GH: &gt; 2.5 μg/L at screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="4.91" upper_limit="22.93"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="33.63"/>
                    <measurement group_id="O3" value="10.3" lower_limit="4.24" upper_limit="20.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Pasireotide LAR overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" lower_limit="16.87" upper_limit="37.68"/>
                    <measurement group_id="O2" value="8.3" lower_limit="0.21" upper_limit="38.48"/>
                    <measurement group_id="O3" value="23.9" lower_limit="15.42" upper_limit="34.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Pasireotide LAR overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="15.77" upper_limit="36.26"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                    <measurement group_id="O3" value="21.6" lower_limit="13.53" upper_limit="31.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Pasireotide LAR overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="14.68" upper_limit="34.82"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                    <measurement group_id="O3" value="20.5" lower_limit="12.60" upper_limit="30.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Change From Baseline in Scores as Measured by Acromegaly Quality of Life (AcroQoL)</title>
        <description>Evaluation of effect of pasireotide LAR on Health Related Quality of Life (HRQoL) was assessed using AcroQoL, an acromegaly-specific quality of life instrument. The AcroQol instrument is comprised of 22 questions divided into two scales: one evaluating physical aspects (8 items) and the other that addresses psychological aspects (14 items). The psychological scale can also be further divided into subscale that evaluates physical appearance and the other subscale focused on the impact of the disease on personal relationships of the patient (7 items each). Each of the questions has a 5-item Likert scale. For each dimension the scores range from 0-4 with 0 being the lowest impact and 4 being the most severe.</description>
        <time_frame>Baseline, Weeks 48, 60 &amp; 72</time_frame>
        <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall - AcroQOL Total Scores</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide LAR Overall - AcroQOL Physical Sub-scores</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O3">
            <title>Pasireotide LAR Overall - AcroQOL Psychological Sub-scores</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall - AcroQOL Psycho/Appearance Sub-scores</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O5">
            <title>Pasireotide LAR Overall-AcroQOL Psycho/Pers Relatns Sub-scores</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Change From Baseline in Scores as Measured by Acromegaly Quality of Life (AcroQoL)</title>
          <description>Evaluation of effect of pasireotide LAR on Health Related Quality of Life (HRQoL) was assessed using AcroQoL, an acromegaly-specific quality of life instrument. The AcroQol instrument is comprised of 22 questions divided into two scales: one evaluating physical aspects (8 items) and the other that addresses psychological aspects (14 items). The psychological scale can also be further divided into subscale that evaluates physical appearance and the other subscale focused on the impact of the disease on personal relationships of the patient (7 items each). Each of the questions has a 5-item Likert scale. For each dimension the scores range from 0-4 with 0 being the lowest impact and 4 being the most severe.</description>
          <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="-7.1" spread="0.00"/>
                    <measurement group_id="O4" value="-3.6" spread="0.00"/>
                    <measurement group_id="O5" value="-10.7" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="9.72"/>
                    <measurement group_id="O2" value="0.9" spread="10.61"/>
                    <measurement group_id="O3" value="1.8" spread="10.60"/>
                    <measurement group_id="O4" value="0.8" spread="12.82"/>
                    <measurement group_id="O5" value="2.9" spread="11.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Percentage of Participants Reporting Levels 1 - 5 by Dimensions of Acromegaly Symptoms</title>
        <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
        <time_frame>Weeks 48, 60 &amp; 72</time_frame>
        <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Headache</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Fatigue</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O3">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Perspiration</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Osteoarthralgia</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O5">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Paresthesiae</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Percentage of Participants Reporting Levels 1 - 5 by Dimensions of Acromegaly Symptoms</title>
          <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
          <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48: None/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="81"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6"/>
                    <measurement group_id="O2" value="59.1"/>
                    <measurement group_id="O3" value="69.3"/>
                    <measurement group_id="O4" value="53.4"/>
                    <measurement group_id="O5" value="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="81"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3"/>
                    <measurement group_id="O2" value="17.0"/>
                    <measurement group_id="O3" value="13.6"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="81"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="9.1"/>
                    <measurement group_id="O4" value="9.1"/>
                    <measurement group_id="O5" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="81"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="81"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="81"/>
                    <count group_id="O5" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: None/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2"/>
                    <measurement group_id="O2" value="48.9"/>
                    <measurement group_id="O3" value="60.2"/>
                    <measurement group_id="O4" value="56.8"/>
                    <measurement group_id="O5" value="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0"/>
                    <measurement group_id="O2" value="20.5"/>
                    <measurement group_id="O3" value="20.5"/>
                    <measurement group_id="O4" value="14.8"/>
                    <measurement group_id="O5" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="13.6"/>
                    <measurement group_id="O3" value="6.8"/>
                    <measurement group_id="O4" value="11.4"/>
                    <measurement group_id="O5" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60: Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: None/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8"/>
                    <measurement group_id="O2" value="44.3"/>
                    <measurement group_id="O3" value="61.4"/>
                    <measurement group_id="O4" value="51.1"/>
                    <measurement group_id="O5" value="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="15.9"/>
                    <measurement group_id="O4" value="20.5"/>
                    <measurement group_id="O5" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="10.2"/>
                    <measurement group_id="O3" value="6.8"/>
                    <measurement group_id="O4" value="10.2"/>
                    <measurement group_id="O5" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72: Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension (Ext.) Phase: Percentage of Participants With Acromegaly Shift Symptoms From Extension Baseline to Most Extreme Post-extension Baseline</title>
        <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
        <time_frame>Weeks 48, 60 &amp; 72</time_frame>
        <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Headache</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O2">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Fatigue</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O3">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Perspiration</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O4">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Osteoarthralgia</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
          <group group_id="O5">
            <title>Pasireotide LAR Overall - Acromegaly Symptom: Paresthsiae</title>
            <description>This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase</description>
          </group>
        </group_list>
        <measure>
          <title>Extension (Ext.) Phase: Percentage of Participants With Acromegaly Shift Symptoms From Extension Baseline to Most Extreme Post-extension Baseline</title>
          <description>Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).</description>
          <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ext. Baseline (BL): Non/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3"/>
                    <measurement group_id="O2" value="56.8"/>
                    <measurement group_id="O3" value="68.2"/>
                    <measurement group_id="O4" value="52.3"/>
                    <measurement group_id="O5" value="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ext. BL: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="20.5"/>
                    <measurement group_id="O4" value="30.7"/>
                    <measurement group_id="O5" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ext. BL: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="10.2"/>
                    <measurement group_id="O4" value="12.5"/>
                    <measurement group_id="O5" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ext. BL: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="1.1"/>
                    <measurement group_id="O4" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ext. BL: Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O4" value="1.1"/>
                    <measurement group_id="O5" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ext. BL: Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Ext. BL: Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL:tot Non/absent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6"/>
                    <measurement group_id="O2" value="51.1"/>
                    <measurement group_id="O3" value="54.5"/>
                    <measurement group_id="O4" value="43.2"/>
                    <measurement group_id="O5" value="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL: total Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="26.1"/>
                    <measurement group_id="O4" value="33.0"/>
                    <measurement group_id="O5" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL: total Mod.</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="14.8"/>
                    <measurement group_id="O4" value="13.6"/>
                    <measurement group_id="O5" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL: total Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="4.5"/>
                    <measurement group_id="O4" value="8.0"/>
                    <measurement group_id="O5" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL: tot. Very severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O4" value="2.3"/>
                    <measurement group_id="O5" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Most extr. post-BL: total Not done</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Change From Baseline in EQ-5D-5L Index Scores</title>
        <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
        <time_frame>Baseline, Weeks 48, 60 &amp; 72</time_frame>
        <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall</title>
            <description>These are the participants in the extension phase who received Pasireotide LAR</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Change From Baseline in EQ-5D-5L Index Scores</title>
          <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
          <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Change From Baseline in EQ-5D-5L VAS Assessment</title>
        <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
        <time_frame>Baseline, Weeks 48, 60 &amp; 72</time_frame>
        <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Pasireotide LAR Overall</title>
            <description>These are the participants in the extension phase who received Pasireotide LAR</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Change From Baseline in EQ-5D-5L VAS Assessment</title>
          <description>Evaluation of effect of pasireotide LAR on health status, measured by EQ-5D-5L, a valid and reliable instrument for measuring general health status. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a 20-cm vertical, visual analogue scale with endpoints labeled 'the best health you can imagine' and 'the worst health you can imagine'. This scale is numbered from 0 to 100. 100 means the best health you can imagine.
0 means the worst health you can imagine.</description>
          <population>Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from first dose of study treatment until end of study treatment plus 84 days post treatment, up to maximum duration of 76 weeks.</time_frame>
      <desc>AE is any sign or symptom that occurs during the study treatment plus the 84 days post treatment.
This is a single-arm study that evaluated the efficacy of Pasireotide LAR 40mmg and 60 mg. The Lanreotide and Octreotide arms were not really arms. These arms represent the drugs that the participants were on before being enrolled in the Pasireotide LAR arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Up-titrated to Pasireotide LAR 60 mg</title>
          <description>Patients not achieving biochemical control and were up-titrated to pasireotide LAR 60 mg.</description>
        </group>
        <group group_id="E2">
          <title>Pasireotide LAR Overall</title>
          <description>This is the sum total of participants in under the previous treatments in the Core phase: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg or who were treated with at least one dose of pasireotide LAR in the extension phase</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nose deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermatofibrosarcoma protuberans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study is a single-arm study to evaluate the safety &amp; efficacy of pasireotide LAR in patients with inadequately controlled acromegaly who were previously on somatostatin analogues: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>826-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

